Login
$AVIR
$4.25 -$0.05 (1.28%) Live

$AVIR SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection

09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

CERTAIN INFORMATION MARKED AS [* * *] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

06 Oct 2026 SCHEDULE 13G
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV

23 Jun 2026 Form 4: Lucidi Bruno, Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Berger Franklin M, Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Berman Howard, Director

Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Duncan Barbara Gayle, Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Polsky Bruce, Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Murphy Polly A., Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Adams Jerome M., Director

Received 29,600 shares by exercise or conversion · Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

23 Jun 2026 Form 4: Kirsch Arthur S, Director

Granted 26,700 Restricted Stock Units · Granted 37,700 Stock Option (Right to Buy)

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented...

21 May 2026 Form 4/A: Murphy Polly A., Director

Bought 6,100 shares ($25.4K)

20 May 2026 Form 4: Murphy Polly A., Director

Bought 6,100 shares ($25.4K)

12 May 2026 10-Q
12 May 2026 8-K: Results of Operations and Financial Condition

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support